和铂医药-B午后涨近6%,年内已回购约1.3亿港元股份,并宣布与Visterra合作,利用其专有技术平台推进生物治疗药物研发,该平台已获临床验证及全球认可。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.